The use of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes and obesity is associated with an ...

GLP-1 compounders find loophole by altering formulations to bypass FDA bans, raising oversight concerns for weight-loss clinics nationwide.

A new report states that older adults using GLP-1 drugs may have a higher risk of loss of muscle mass, malnutrition, ...

Gov. Greg Abbott said protecting lives remains the state’s top priority as life-threatening flooding continues.

UVM Health expects to save $19 million a year by cutting GLP-1 coverage for employees. But does that figure account for the medical costs patients avoid once the treatment works?

Novo Nordisk is a leader in the GLP-1 market, but the company has experienced several clinical setbacks over the past 18 ...

MindWalk will report Q4 and full fiscal year 2026 results on July 22, 2026, giving investors a near-term look at the company's revenue traje ...

During an on-site inspection, investigators found that the semaglutide was manufactured in an unnamed lab not registered with the FDA.

A wave of new research and policy developments is reshaping how health system leaders think about GLP-1 medications — from telehealth prescribing gaps to Medicare’s new coverage bridge. Here are six ...

Three Indian pharmaceutical companies, Dr. Reddy's Laboratories, Torrent Pharmaceuticals and USV, have initiated voluntary ...

GLP-1 receptor agonists promote weight loss via gut-hormone mimetics that curb appetite, slow gastric emptying, and improve ...

GLP-1 agonists have become popular treatments for weight loss and type 2 diabetes, and newer studies suggest other health ...